Real world data reflects the transition from a very limited and well-defined patient population in clinical trials to the broader population where there is less control over multiple clinical factors. Phase IV studies, an integral aspect of Health Economics and Outcomes Research (HEOR), evaluate outcomes and provide vigilance over medical regimens in the broader population after FDA approval of an agent or medical device. Ongoing vigilance includes monitoring the efficacy and potentially identifying toxicities not previously observed among smaller patient cohorts within clinical trials. The analysis of clinical outcomes from massive national datasets provides insight for therapeutic strategies and impacts medical practice patterns.
Medical practice patterns are also influenced by healthcare economics and policy. Broad population-based HEOR analyses provide critical information regarding the distribution and use of limited healthcare resources. Utilization of limited healthcare resources, a critical factor in response to the Covid-19 pandemic, is foundational in all healthcare policy discussions. Founded 14 years ago, STATinMED Research has been at the forefront of HEOR and is one of the world’s most trusted health HEOR companies. STATinMED Research built its credibility in HEOR by developing statistical methodologies that address complex issues. Unlike others in HEOR, STATinMED Research was known to be data agnostic, having access to more than 35 data sets.
Working with unique and innovative datasets, STATinMED Research is able to provide relevant data for unique clinical queries.
Our objective of working with pharmaceutical manufacturers is to provide consultative input and feedbacks to help them understand the key strategic information of their drugs
STATinMED Research assists its pharma clients by analyzing and interpreting data derived from real world evidence. Through its impressive network, STATinMED Research also provides internationally recognized Key Opinion Leaders as thought leadership during the conduct of the study. “Our objective of working with pharmaceutical manufacturers is to provide consultative input, and to relay the key value message of our scientific findings,” says Jason Drenning, Senior Vice President, Corporate Development & Operations at STATinMED Research.
Using a strong tool for creating interactive dashboards and innovative data visualization, STATinMED Research has expertise in oncology, cardiology and coagulopathies, immunology, infectious diseases, mental health and diabetes. Having a median Impact Factor of 4, scientific findings from STATinMED Research’s real world data analytics and publications impact medical practice guidelines and health policy. Completely committed to improving patient outcomes, STATinMED Research shares in the steadfast dedication of its clients to integrity and transparency.